HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $14.51 and traded as high as $16.85. HUTCHMED shares last traded at $16.75, with a volume of 66,974 shares changing hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered HUTCHMED from a "buy" rating to a "hold" rating in a research note on Monday, November 18th.
Read Our Latest Analysis on HCM
HUTCHMED Trading Up 3.2 %
The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The business has a 50 day moving average of $14.58 and a 200 day moving average of $16.64.
Institutional Trading of HUTCHMED
A number of large investors have recently made changes to their positions in HCM. M&G PLC boosted its stake in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company's stock worth $5,345,000 after buying an additional 132,333 shares during the last quarter. Jane Street Group LLC boosted its stake in HUTCHMED by 362.2% in the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock worth $1,305,000 after buying an additional 49,366 shares during the last quarter. XY Capital Ltd acquired a new stake in HUTCHMED in the 4th quarter worth about $673,000. ABC Arbitrage SA acquired a new stake in HUTCHMED in the 4th quarter worth about $500,000. Finally, Renaissance Technologies LLC boosted its stake in HUTCHMED by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock worth $2,717,000 after buying an additional 29,239 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Recommended Stories
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
